Annals of Oncology

Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
pp. 845-846(2)
Author: Punt, C. J. A.

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results
pp. 847-862(16)
Authors: Mosolits, S.; Ullenhag, G.; Mellstedt, H.

Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review
pp. 863-868(6)
Authors: Hoei-Hansen, C. E.; Rajpert-De Meyts, E.; Daugaard, G.; Skakkebaek, N. E.

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
pp. 869-877(9)
Authors: Kalofonos, H.P.; Aravantinos, G.; Kosmidis, P.; Papakostas, P.; Economopoulos, T.; Dimopoulos, M.; Skarlos, D.; Bamias, A.; Pectasides, D.; Chalkidou, S.; Karina, M.; Koutras, A.; Samantas, E.; Bacoyiannis, C.; Samelis, G.F.; Basdanis, G.; Kalfarentzos, F.; Fountzilas, G.

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
pp. 878-886(9)
Authors: Comella, P.; Massidda, B.; Filippelli, G.; Palmeri, S.; Natale, D.; Farris, A.; De Vita, F.; Buzzi, F.; Tafuto, S.; Maiorino, L.; Mancarella, S.; Leo, S.; Lorusso, V.; De Lucia, L.; Roselli, M.

Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
pp. 887-892(6)
Authors: Ruzzo, A.; Graziano, F.; Pizzagalli, F.; Santini, D.; Battistelli, V.; Panunzi, S.; Canestrari, E.; Catalano, V.; Humar, B.; Ficarelli, R.; Bearzi, I.; Cascinu, S.; Naldi, N.; Testa, E.; Magnani, M.

Tumour budding detected by laminin-5 2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer
pp. 893-898(6)
Authors: Nilsson, P. J.; Rubio, C.; Lenander, C.; Auer, G.; Glimelius, B.

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study
pp. 899-908(10)
Authors: Feher, O.; Vodvarka, P.; Jassem, J.; Morack, G.; Advani, S. H.; Khoo, K. S.; Doval, D. C.; Ermisch, S.; Roychowdhury, D.; Miller, M. A.; von Minckwitz, G.

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
pp. 909-914(6)
Authors: Norum, J.; Risberg, T.; Olsen, J. A.

Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)
pp. 915-922(8)
Authors: Bonneterre, J.; Bercez, C.; Bonneterre, M.-E.; Lenne, X.; Dervaux, B.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
pp. 923-927(5)
Authors: Manegold, C.; Symanowski, J.; Gatzemeier, U.; Reck, M.; von Pawel, J.; Kortsik, C.; Nackaerts, K.; Lianes, P.; Vogelzang, N. J.

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
pp. 928-933(6)
Authors: Hara, S.; Oya, M.; Mizuno, R.; Horiguchi, A.; Marumo, K.; Murai, M.

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
pp. 934-941(8)
Authors: Etienne-Grimaldi, M.-C.; Pereira, S.; Magné, N.; Formento, J.-L.; Francoual, M.; Fontana, X.; Demard, F.; Dassonville, O.; Poissonnet, G.; Santini, J.; Bensadoun, R.-J.; Szepetowski, P.; Milano, G.

Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide
pp. 942-949(8)
Authors: Brada, M.; Ashley, S.; Dowe, A.; Gonsalves, A.; Huchet, A.; Pesce, G.; Reni, M.; Saran, F.; Wharram, B.; Wilkins, M.; Wilkins, P.

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group
pp. 950-957(8)
Authors: Bafaloukos, D.; Tsoutsos, D.; Kalofonos, H.; Chalkidou, S.; Panagiotou, P.; Linardou, E.; Briassoulis, E.; Efstathiou, E.; Polyzos, A.; Fountzilas, G.; Christodoulou, C.; Kouroussis, C.; Iconomou, T.; Gogas, H.

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
pp. 958-965(8)
Authors: Desai, A. A.; Schilsky, R. L.; Young, A.; Janisch, L.; Stadler, W. M.; Vogelzang, N. J.; Cadden, S.; Wright, J. A.; Ratain, M. J.

Predictors of prescription of morphine for severe cancer pain by physicians in Korea
pp. 966-971(6)
Authors: Yun, Y. H.; Park, S. M.; Lee, K.; Chang, Y. J.; Heo, D. S.; Kim, S.-Y.; Hong, Y. S.; Huh, B. Y.

Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group
pp. 972-980(9)
Authors: Cleeland, C. S.; Portenoy, R. K.; Rue, M.; Mendoza, T. R.; Weller, E.; Payne, R.; Kirshner, J.; Atkins, J. N.; Johnson, P. A.; Marcus, A.

Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium
pp. 981-986(6)
Authors: Brenner, H.; Stegmaier, C.; Ziegler, H.

Reply to the Letter to the Editor on Safety of sentinel node biopsy in pregnant patients, by G. Dubernard et al. (Ann Oncol 2005; 16: 987)
pp. 987-988(2)
Authors: Paganelli, G.; Cremonesi, M.; Ferrari, M.; Trifirò, G.; Gentilini, O.; Luini, A.

Safety of sentinel node biopsy in pregnant patients
pp. 987-987(1)
Authors: Dubernard, G.; Garbay, J. R.; Rouzier, R.; Delaloge, S.

Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis
pp. 988-989(2)
Authors: Chen, C.-C.; Chang, J.-Y.; Liu, K.-J.; Chan, C.; Ho, C.-H.; Lee, S.-C.; Chen, L.-T.

Limitations of Wright formula estimates of renal function
pp. 989-990(2)
Authors: Dooley, M. J.; Poole, S. G.

Reply to the letter “Limitations of bedside estimates of renal function”, by M. J. Dooley and S. G. Poole (doi:10.1093/annonc/mdi173)
pp. 990-990(1)
Authors: Marx, G. M.; Steer, C. B.; Harper, P. G.

Quality of cancer care
pp. 991-991(1)
Authors: Gorodokin, G. I.; Novik, A. A.

The Complete Guide to Relieving Cancer Pain and Suffering
pp. 992-992(1)
Author: Wilson, R.

Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
pp. 993-993(1)

Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)
pp. 993-993(1)